Millions in South Africa face rising diabetes treatment costs and limited access to insulin pens, sparking protests.
It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...
A new study has shed light on the health risks faced by people who stop using weight-loss medications Ozempic or Wegovy.
Ministers have been urged to ditch "gimmicks and soundbites" while addressing the soaring cost of obesity to the NHS.
KEY BUSINESS HIGHLIGHTSPhase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to ...
Researchers said the analysis lays bare a ‘decades-long-failure’ to tackle the overweight and obesity epidemic ...
With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...
With new weight-loss drugs hailed as ‘miracle’ medicines, Harriet Symonds explores whether their increasing popularity should ...
There’s been talk of GLP-1 and semaglutide drugs, like Ozempic ... His patients typically notice the results after three ...
Weight-loss drugs Ozempic and Wegovy have become popular worldwide. Many people have also reported suffering some serious ...
Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback